The Clinical Effect of Deferoxamine Mesylate on Edema after Intracerebral Hemorrhage

Abstract

Background and PurposeIt has been shown that 3 days of 62 mg/kg/day deferoxamine infusion (maximum dose not to exceed 6000 mg/day) is safe and tolerated by intracerebral hemorrhage (ICH) patients. The aim of this study was to investigate the efficacy of deferoxamine mesylate for edema resolution and hematoma absorption after ICH.MethodsFrom February 2013 to May 2014, spontaneous ICH patients diagnosed by computed tomography (CT) within 18 hours of onset were evaluated. Patients were randomly divided into two groups: an experimental group and a control group. The treatment of the two groups was similar except that the experimental group received deferoxamine mesylate. Patients were evaluated by CT and neurology scale at the time of admission, and on the fourth, eighth, and fifteenth day (or at discharge) after admission. Patients were followed up for the first 30 days and clinical data of the two groups were compared.ResultsForty-two patients completed 30 days of follow-up by May 2014; 21 cases in the experimental group and 21 cases in the control group. The control group’s relative edema volume on the fifteenth day (or discharge) was 10.26 ± 17.54, which was higher than the experimental group (1.91 ± 1.94; P < 0.05). The control group’s 1–8 day and 8–15 day relative hematoma absorption were greater than the experimental group (P < 0.05).The control group’s relative edema volume on the fourth, eighth, and fifteenth day (or discharge) was higher than the experimental group (P < 0.05). Neurological scores between the two groups were not statistically different on the fifteenth day (or discharge) or on the thirtieth day.ConclusionsDeferoxamine mesylate may slow hematoma absorption and inhibit edema after ICH, although further investigation is required to form definitive conclusions.Trial RegistrationChinese Clinical Trial Registry ChiCTR-TRC-14004979

Brain iron overload following intracranial haemorrhage

“…In that trial, there were some concerns over the occurrence of acute respiratory distress syndrome and currently, a lower dose of DFX is being tested in the Intracerebral Hemorrhage Deferoxamine Trial (iDEF; NCT02175225). In addition, a recent 42 patients study investigating DFX treatment for ICH concluded that DFX may slow haematoma absorption and inhibit oedema formation 192. Aside from these trials, there have been no other large-scale attempts to implement this treatment into human patients in ICrH.…”

Acute Management of Anticoagulation-Associated Intracerebral Hemorrhage

“…A current subanalysis of the INTERACT 2 data identified associations with an improved outcome for mannitol, at least for larger bleeds ( > 15 ml) [94]. Promising data has emerged from cohort and pilot studies for hypertonic sodium chloride infusions, among others, deferoxamine (recently published), and mild, prolonged hypothermia [88,95,96]. A current review identified 18 studies on the influence of hypothermia on edema after ICH.…”

Intracerebral Hemorrhage: Perihemorrhagic Edema and Secondary Hematoma Expansion: From Bench Work to Ongoing Controversies

“…A phase-I study of 20 patients found deferoxamine (7–62 mg/kg/day) to be safe in ICH patients (75). A controlled study of 42 patients showed slowing of hematoma absorption and reduction in PHE using deferoxamine without any clinical benefit (76). Currently, two controlled trials are ongoing to study the effect of deferoxamine on PHE and long-term clinical outcomes (77, 78).…”